

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

C-Nucleoside Analogues of Nicotinamide Mononucleotide (NMN)

Krzysztof W. Pankiewicz^a; Marek M. Kabat^a; Elzbieta Sochacka^a; Lech Ciszewski^a; Joanna Zeidler^a; Kyoichi A. Watanabe^a

^a Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division of Graduate School of Medical Sciences, Cornell University, New York, NY, U.S.A.

To cite this Article Pankiewicz, Krzysztof W. , Kabat, Marek M. , Sochacka, Elzbieta , Ciszewski, Lech , Zeidler, Joanna and Watanabe, Kyoichi A.(1988) 'C-Nucleoside Analogues of Nicotinamide Mononucleotide (NMN)', *Nucleosides, Nucleotides and Nucleic Acids*, 7: 5, 589 — 593

To link to this Article: DOI: 10.1080/07328318808056291

URL: <http://dx.doi.org/10.1080/07328318808056291>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

C-NUCLEOSIDE ANALOGUES OF NICOTINAMIDE MONONUCLEOTIDE (NMN).

Krzysztof W. Pankiewicz, Marek M. Kabat, Elzbieta Sochacka
Lech Ciszewski, Joanna Zeidler and Kyoichi A. Watanabe*

Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer
Center, Sloan-Kettering Division of Graduate School of Medical
Sciences, Cornell University, New York, NY, 10021, U.S.A.

ABSTRACT

5-(β -D-Ribofuranosyl)nicotinamide (IIc) and 6-(β -D-ribofuranosyl)picolinamide (IIId) and their corresponding α -isomers (III) were synthesized from ribonolactone. The C-nucleoside IIc was further converted to its 5'-monophosphate IIp which is isosteric to NMN (Ip).

We reported the synthesis of 5-(β -D-ribofuranosyl)nicotinamide (IIc) and its N-methylated derivative, from 2,4:3,5-di-O-benzylidene-D-aldehydoribose, as the C-nucleoside analogues isosteric and isoelectronic to nicotinamide riboside (I, Figure 1).¹ Similar synthesis of several 2-D-ribofuranosylpyridines were also reported.² These synthetic procedures which require preparation of the aldehydoribose are not amenable for large-scale preparations.

In order to prepare IIc more efficiently, we investigated a new approach starting from the commercially available D-ribonolactone' (1, Scheme 1). 2,3-O-Isopropylidene-5-O-(tert-butyl-dimethyl)silyl-D-ribonolactone (2)⁴ was prepared in two steps from 1. Upon reaction of 2 with 3-cyano-5-lithiopyridine, 1-(3-






Fig.1



Scheme 1


cyanopyridin-5-yl)-2,3-O-isopropylidene-5-O-(tert-butyldimethyl)-silyl-β-D-ribo-furanose (**3a**) was obtained in 79% yield as the sole product. The anomeric configuration of **3a** was established by the following: Desilylation of **3a** with Et₃NHF to **4a** followed by mesylation afforded the mesylate **5a** which was converted in high yield into the 1,5-anhydro derivative **6a** by treatment with DBU in CH₂Cl₂.

Addition of 3-cyano-5-lithiopyridine with 2,3-O-isopropylidene-5-O-tetrahydropyranyl-D-ribonolactone (**7**)³ afforded a


diastomeric mixture of **8a**. Treatment of **8a** with NaBH₄ afforded a mixture **9a** (Scheme 2) of the allo and altro isomers in about 1:1 ratio. After separation of these epimers on a silica gel column, each isomer was separately treated with TsOH/MeOH to **10a** and then with acetone/TsOH to give the respective 2,3:4,5-di-O-isopropylidene derivative **11a** which was mesylated to **12a**. Solvolysis of allo-**12a** with trifluoroacetic acid in CH₂Cl₂ afforded exclusively the α-C-nucleoside **IIIa**. Similarly, altro-**12a** was exclusively converted into the β-C-nucleoside **IIa**.

In the same series of reactions of **7** with 2-bromo-6-lithio-pyridine, similar results were obtained (Scheme 2). The major difference between the two pyridine derivatives was the allo-altro ratio in the product of NaBH₄ reduction of the pyridinyl-β-D-ribose. 1-(2-Bromopyridin-6-yl)-β-D-ribofuranose (**8b**) gave a 4:1 allo/altro mixture **9b**. Conversion of the 2-bromo or 3-cyano substituent into carboxamide function was performed by the reported procedure.¹

This approach to the synthesis of **IId**, however, was very unsatisfactory, since only one fifth of **9b** gives the β-C-nucleoside. We, therefore, investigated the possibility to convert the allo isomer **9** into the altro counterpart. Attempts at nucleophilic displacement of the mesyl group in allo-**12b** with ⁻OAc resulted in the formation of 1,2-olefin **13b** (Scheme 3). Treatment of allo-**12b** with a better nucleophile ⁻N₃, however, afforded the 1'-azido derivative **14** in good yield, suggesting that the mesyl group in **12b** could be replaceable with a potent oxygen nucleophile. Actually, when allo-**12b** was treated with potassium superoxide (KO₂) and 18-crown-6, according to the procedure of Corey *et al.*,⁴ afforded altro-**11b** together with the new olefin **15**. Although the yield of conversion from allo-**12b** to altro-**11b** was low (24%), this represents the first example of the synthesis of β-C-nucleoside from the allo intermediate. Phosphorylation of



Scheme 2



Scheme 3

IIc by the Yoshikawa procedure⁶ modified by Marquez et al.,⁷ with POCl₃ in trimethyl phosphate afforded the C-nucleotide analogue of NMN.

ACKNOWLEDGMENT

This investigation was supported in part by funds from the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Grants Nos. CA-08748 and CA-33907.

REFERENCES

1. Kabat, M. M., Pankiewicz, K. W., Watanabe, K. A. (1987) J. Med. Chem., 30, 924.
2. Belmans, M., Vrijens, I., Esmans, E. L., Lepoivre, J. A., Alderweireldt, F. C., Wotring, L. L., Townsend, L. B. (1987) Nucleosides Nucleotides, 6, 245.
3. Reaction of a sugar lactone with lithiopyridine was first reported by Ogura et al.: Ogura, H., Takahashi, H., Itoh, T. (1972) J. Org. Chem., 37, 72; Ogura, H., Takahashi, H. (1974) J. Org. Chem., 39, 1374.
4. Wilcox, C. S., Long, G. W., Suh, H. (1984) Tetrahedron Lett., 25, 395.
5. Corey, E. J., Nicolaon, K. S., Shibasaki, M., Machida, Y., Shiner, C. S. (1975) Tetrahedron Lett., 3183.
6. Yoshikawa, M., Kato, T., Takenishi, T. (1967) Tetrahedron Lett., 5065.
7. Gebeyehu, G., Marquez, V. E., Kelly, J. A., Cooney, D. A., Jayaram, H. N., Johns, D. G. (1983) J. Med. Chem., 26, 922.